From Theranostics to Immunotheranostics: the Concept

다국어 초록 (Multilingual Abstract)

Immunotheranostics will be an important development in the future of nuclear medicine and medical oncology. It describes the synergy of theranostic procedures in nuclear medicine and immune oncology (IO) treatment. In brief, it takes advantage of molecular imaging and subsequent targeted modulation of the—in most cases immunosuppressive—tumor microenvironment (TME) by diagnostic and therapeutic radioisotopes. This is of high importance since only a fraction of patients receiving IO is currently being cured by this exciting therapy option. We therefore envision the concept of immunotheranostics as a powerful mean to augment the success of IO treatment in the future and thus the urgent need to further develop the interaction and joint action of nuclear medicine and medical oncology for substantially improved therapy outcome for cancer patients.

참고문헌 (Reference)

1 Hofman MS, "[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer(LuPSMA trial) : a single-centre, single-arm, phase 2 study" 19 : 825-833, 2018

2 Niemeijer AN, "Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer" 9 : 4664-, 2018

3 Heck MM, "Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer" 75 : 920-926, 2019

4 Zhang J, "The influence of microenvironment on tumor immunotherapy" 286 : 4160-4175, 2019

5 Lanitis E, "Targeting the tumor vasculature to enhance T cell activity" 33 : 55-63, 2015

6 Xia A, "T cell dysfunction in cancer immunity and immunotherapy" 10 : 1719-, 2019

7 Teichgräber V, "Specific inhibition of fibroblast activation protein(FAP)-alpha prevents tumor progression in vitro" 60 : 264-272, 2015

8 Herrera FG, "Radiotherapy combination opportunities leveraging immunity for the next oncology practice" 67 : 65-85, 2017

9 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists" 51 : 987-994, 2010

10 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma : opinions of nuclear medicine physicians and radiation oncologists" 52 : 830-838, 2011

11 Conway RE, "Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction" 26 : 5310-5324, 2006

12 Strosberg J, "Phase 3 trial of(177)Lu-dotatate for midgut neuroendocrine tumors" 376 : 125-135, 2017

13 DeriMA, "PETimaging with 89Zr : fromradiochemistry to the clinic" 40 : 3-14, 2013

14 Blykers A, "PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18Fradiolabeled camelid single-domain antibody fragments" 56 : 1265-1271, 2015

15 Zhang C, "Noninvasive imaging of CD206-positiveM2macrophages as an early biomarker for post-chemotherapy tumor relapse and lymph node metastasis" 7 : 4276-4288, 2017

16 Emmett L, "Lutetium177PSMA radionuclide therapy for men with prostate cancer : a review of the current literature and discussion of practical aspects of therapy" 64 : 52-60, 2017

17 Klug F, "Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective Tcell immunotherapy" 24 : 589-602, 2013

18 Calais J, "FAP : the next billion dollar nuclear theranostics target" 61 : 163-165, 2020

19 Jiao D, "Expression of prostate-specificmembrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma" 10 : e00041-, 2019

20 Tavare R, "An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy" 76 : 73-82, 2016

21 Bensch F, "89Zr-atezolizumab imaging as a noninvasive approach to assess clinical response to PD-L1 blockade in cancer" 24 : 1852-1858, 2018

22 Kratochwil C, "225Ac-PSMA-617 for PSMA-targeted-radiation therapy of metastatic castration-resistant prostate cancer" 57 : 1941-1944, 2016

23 Giesel FL, "(68)Ga-FAPI PET/CT : biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers" 60 : 386-392, 2019